Globeflex Capital’s AnaptysBio ANAB Stock Holding History

Globeflex Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-41,359	Closed	-$924K	–	471
2020 Q2	$924K	Buy	+41,359	New	+$756K	0.23%	139

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Globeflex Capital's ANAB Position: Q3 2020 in Review

Globeflex Capital sold out of AnaptysBio (ANAB) in Q3 2020, closing a stake of 41,359 shares — an estimated $924K sold.

Globeflex Capital first reported a position in ANAB in Q2 2020 and held it in 1 quarter. The position peaked at $924K in Q2 2020. 132 funds tracked by Wall St. Rank hold ANAB as of Q3 2020.

Globeflex Capital reported no remaining AnaptysBio position as of Q3 2020 after selling out during the quarter.
Globeflex Capital sold 41,359 AnaptysBio shares in Q3 2020, an estimated $924K.
Globeflex Capital first reported a position in AnaptysBio in Q2 2020 and held it in 1 quarter.
Globeflex Capital's AnaptysBio position peaked at $924K in Q2 2020.
132 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2020.

Based on Globeflex Capital's 13F filing for Q3 2020, filed 13 Nov 2020.